The early 20th century marked a transformative period in medicine, characterized by burgeoning scientific understanding and the advent of effective treatments for previously fatal conditions. Among these breakthroughs, the discovery of insulin in 1921 by Frederick Banting and Charles Best at the University of Toronto stood as a monumental achievement, offering a lifeline to millions afflicted by diabetes mellitus. Prior to this, a diagnosis of type 1 diabetes was a death sentence, with patients typically succumbing within a few years. The immediate global race to produce and distribute insulin, a complex protein, for therapeutic use set the stage for the establishment of two pivotal Danish enterprises: Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. The initial discovery was quickly followed by intense efforts to scale production, as the demand was unprecedented. Major pharmaceutical companies globally, such as Eli Lilly in the United States, secured early licenses and were instrumental in industrializing production. The challenge was not just scientific discovery but consistent, sterile, and affordable mass production. Early insulin preparations, often referred to as "extracts," varied significantly in purity, leading to potential side effects. This urgency, driven by millions of diabetes patients worldwide, created an entirely new global pharmaceutical market, and Denmark, with its advanced medical research and burgeoning pharmaceutical industry, was uniquely poised to be a significant player.
Nordisk Insulinlaboratorium traces its origins to the dedication of August Krogh, a distinguished Danish physiologist and Nobel laureate, and Dr. Hans Christian Hagedorn, a physician and researcher. August Krogh (1874-1949), a renowned physiologist, had received the Nobel Prize in 1920 for his groundbreaking work on the capillary motor-regulating mechanism, underscoring his considerable scientific gravitas and international standing. Krogh's motivation was deeply personal, as his wife, Marie Krogh (1876-1943), herself a respected physician and physiologist, had traveled to Toronto in late 1922 to witness the miraculous effects of insulin firsthand and observe the nascent production methods. While often cited as having type 1 diabetes, it is generally accepted she had severe type 2 diabetes, for which insulin was critical for management. Her personal battle fueled their determination. Witnessing its potential, August Krogh leveraged his scientific network and reputation to secure a non-exclusive license from the University of Toronto in December 1922, granting him permission to produce insulin in Scandinavia. This license was notably granted for humanitarian purposes, emphasizing accessibility over pure commercial gain, which aligned perfectly with Nordisk's foundational ethos. Upon his return to Denmark, Krogh partnered with Hagedorn (1888-1971), a clinician and biochemist already working on blood sugar regulation and who had developed a precise method for measuring blood sugar, making him an ideal collaborator. Hagedorn's scientific rigor and methodical approach were instrumental in developing a reliable method for insulin extraction and purification from animal pancreases, notably employing an isoelectric precipitation method which significantly improved product purity.
Their shared vision was not solely commercial; a strong philanthropic impulse underpinned Nordisk's initial efforts. The company was formally established on March 15, 1923, as Nordisk Insulinlaboratorium. Its operational model was unique for its time, functioning effectively as a non-profit entity dedicated to ensuring that insulin was affordable and widely available to Danish patients. This was crucial given the severe economic depression following World War I, which would have made expensive imported insulin prohibitive for many citizens. This ethos was reflected in the institutional support they garnered, including backing from the Danish state, which provided significant grants recognizing the public health imperative. The Rockefeller Foundation, known for its global health initiatives, also contributed, seeing Nordisk as a model for public-spirited pharmaceutical production. Other private benefactors, often moved by personal experiences with diabetes, provided additional capital. This collective support allowed for the establishment of a state-of-the-art laboratory and production facility in Gentofte, Copenhagen, equipped with the latest scientific instrumentation for biochemical purification and quality control. The scientific community, including luminaries like August Krogh, aimed to ensure that this life-saving drug would be produced to the highest standards of purity and efficacy. Their initial team consisted of a small group of scientists, technicians, and support staff, rapidly initiating production.
Simultaneously, a parallel entrepreneurial venture was taking shape, driven by the Pedersen brothers: Harald Pedersen, an engineer, and Thorvald Pedersen, a pharmacist. Harald Pedersen (1887-1966), a highly skilled mechanical engineer, had prior experience designing specialized industrial machinery, including equipment for dairies and breweries. Thorvald Pedersen (1887-1961), a pharmacist, possessed critical knowledge of chemical processes and pharmaceutical formulation. Both had initially contributed their expertise to Nordisk's nascent operations; Harald designed and built specialized equipment for insulin extraction, and Thorvald assisted with preliminary production processes. However, differing perspectives on commercial scale and operational independence led them to pursue their own path. The Pedersen brothers, driven by a more direct entrepreneurial spirit and a belief in rapid, large-scale industrialization, felt that Nordisk's academic and philanthropic model might not be agile enough to efficiently meet the burgeoning commercial demand. They believed they could develop more efficient and larger-scale production methods, leveraging Harald’s engineering prowess for industrial processing and Thorvald’s pharmaceutical knowledge for product formulation and quality control.
In May 1923, the Pedersen brothers established Novo Terapeutisk Laboratorium. Their decision to form a separate entity was a bold move, marking the beginning of a competitive dynamic within the nascent Danish insulin market. Their approach was characterized by an emphasis on industrial innovation and an agile business model, distinguishing them from the more academically rooted Nordisk. They independently refined their own insulin extraction techniques, focusing on developing a proprietary process. Harald Pedersen leveraged his engineering expertise to design and construct their sophisticated production apparatus, distinct from Nordisk's, while Thorvald Pedersen refined the chemical purification methods, resulting in a product they named "Novo Insulin." Their aim was a high-purity product that could be produced consistently and scaled up rapidly to meet both domestic and international market needs. While Nordisk prioritized a non-profit, public health model, Novo embraced a more conventional commercial structure, seeking to penetrate the market with an efficiently produced, high-quality product. The competitive yet complementary emergence of these two enterprises underscored the significant demand for insulin and the rapid scientific and industrial advancements occurring in Denmark.
Early challenges for both Nordisk and Novo included scaling production to meet surging demand, refining purification processes to minimize adverse reactions, and standardizing dosage to ensure consistent therapeutic effects. Raw material sourcing was a significant hurdle; millions of animal pancreases (primarily from pigs and cattle) were required annually, necessitating complex supply agreements with slaughterhouses across Denmark and eventually Europe. The limited yield of insulin per pancreas, often measured in milligrams, meant enormous quantities of raw material had to be processed and logistical complexities for transport and storage were substantial. Purification was another major issue; early insulin preparations often contained impurities that led to allergic reactions, local irritation at injection sites, and inconsistent therapeutic effects. Both companies invested heavily in research to refine their extraction and purification techniques, employing nascent biochemical methods to minimize contaminants. Standardization was equally critical; the lack of a universally accepted unit for insulin dosage initially created confusion. Nordisk and Novo, like other producers globally, had to work towards consistent potency measurement, often using animal bioassays, to ensure that patients received predictable and effective doses, thereby building physician and patient trust in their respective products. The biological nature of insulin production, involving intricate extraction from animal glands, presented considerable hurdles in maintaining consistency and purity. Securing reliable supplies of raw materials and establishing robust quality control mechanisms were paramount for both organizations as they sought to establish credibility in a critical new therapeutic market. The logistical complexity of maintaining a sterile and consistent cold chain for a biological product also necessitated significant infrastructure investment.
By the end of 1923, both Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium were officially established entities, each successfully producing and distributing insulin in Denmark. Nordisk, with its robust scientific backing and philanthropic mission, focused on delivering high-quality, affordable insulin to Danish patients, supported by governmental and philanthropic funding. Novo, driven by the Pedersen brothers' entrepreneurial vision, rapidly scaled up production with an emphasis on industrial efficiency and a commercial market approach. Their independent formations marked the genesis of what would eventually become a single, unified pharmaceutical powerhouse. This period of dual emergence created a competitive landscape in Denmark that fostered rapid innovation in insulin production technology and purity standards. While distinct in their initial operating philosophies and market strategies, both companies shared an overarching commitment to providing life-saving medication. The stage was set for an era of innovation and competitive development in diabetes care, driven by two distinct yet equally committed Danish companies dedicated to transforming a once-fatal condition into a manageable one, and eventually positioning them for international competition.